AstraZeneca gets cozy with bloggers; Deborah Dunsire new CEO at EnVivo;

 @FiercePharma: Pharma, FDA still lag in post-marketing safety studies. Getting better, but large % unfinished--or not begun. Yesterday's story | Follow @FiercePharma

 @CarlyHFierce: NICE says 'no' to Celgene's Revlimid. Article | Follow @CarlyHFierce

> Regulators in Sweden have questioned why the European Medicines Agency would permit doctors to again use Bayer's Trasylol, which was suspended several years ago. Story

> Indian drugmakers Sun Pharma and Lupin have hit trading highs in India. Story

> Tris Pharma has launched dextroamphetamine sulfate oral solution, the first generic of the ADHD drug ProCentra. Release

> Deborah Dunsire, who just two months ago left Takeda's Millennium, has been tapped as the new CEO at EnVivo Pharmaceuticals. Story

Medical Device News

 @FierceMedDev: ICYM this week's M&A feature - Blockbusters and bloodlettings: A look at 2013's hot start. Special report | Follow @FierceMedDev

 @MarkHFierce: Only a few weeks left to nominate a company for this year's FMD Fierce 15. Submit your nomination | Follow @MarkHFierce

 @DamianFierce: Device outfit CVRx has raised $29.6M in a round led by NEA and J&J. Article | Follow @DamianFierce

> Report: Baxter's $4B bid for Gambro to win EU approval. More

> Stentys' self-apposing cardiac stent gains expanded CE mark indications. Item

> VisionCare discloses CMS coverage plan for implantable miniature telescope. Story

> Myriad targets Gene By Gene in second BRCA patent suit. Report

Biotech News

 @FierceBiotech: 2013 Biotech IPOs: The biotech IPO scene turns red hot. Special report | Follow @FierceBiotech

 @JohnCFierce: Deborah Dunsire makes quick leap from Millennium to fast-growing EnVivo. News | Follow @JohnCFierce

 @RyanMFierce: Alnylam Pharma spotlights more upbeat human data or gene-silencing drugs. Story | Follow @RyanMFierce

 @EmilyMFierce: Anti-leukemia compound could also treat common breast cancers. Story | Follow @EmilyMFierce

> Rockwell Medical shares spike on positive PhIII data. Item

> EU, pharma industry pledge $4.4B for R&D projects. Story

> Booming China poised to take a top position in global drug R&D. Article

Pharma Manufacturing News

 @EricPFierce: BioPlan says China, India losing luster for outsourced biopharmaceutical manufacturing. More | Follow @EricPFierce

> Wockhardt faces 2nd import alert. Report

> Sanofi's ImmuCyst available in next year, Alliance Pharma says. More

> Pfizer to invest $130M in 2 plants in Ireland. News

> Contract manufacturer Piramal also into development, cellphones. Story

Vaccines News

> Manufacturers prepare for resurgence of H7N9. News

> Robot eases kids' vaccination distress in study. More

> Novartis inks typhoid vax licensing deal with Biological E. Story

> U.K. mumps outbreak linked to waning MMR protection. Report

And Finally... AstraZeneca ($AZN) hosted what it labeled the "Inaugural Breast Cancer Blogger Summit," in which it invited a contingent of breast cancer bloggers to its offices in Fairfax, DE, to talk about what it is doing with breast cancer treatments, among other things. Report

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.